Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CASP5 | P51878 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616300 | 0.96 | CHRM5 (0.56) | ACHECHRM5ADRA2CNCF1SMN1; SMN2 | |
| SCHEMBL12772838 | 0.91 | CHRM5 (0.62) | ACHECHRM5ADRA2CNCF1SMN1; SMN2 | |
| SCHEMBL24319476 | 0.91 | NCF1 (0.50) | ACHECHRM5ADRA2CNCF1CACNA2D1 | |
| SCHEMBL25141738 | 0.89 | CHRM5 (0.50) | ACHECHRM5ADRA2CNCF1SMN1; SMN2 | |
| SCHEMBL1777579 | 0.89 | CHRM5 (0.67) | ACHECHRM5ADRA2CSMN1; SMN2OPRM1 | |
| SCHEMBL3436997 | 0.89 | NCF1 (0.52) | ACHECHRM5ADRA2CNCF1CACNA2D1 | |
| SCHEMBL4401614 | 0.86 | CHRM5 (0.48) | ACHECHRM5ADRA2CNCF1CACNA2D1 | |
| SCHEMBL23173902 | 0.86 | NCF1 (0.54) | ACHECHRM5ADRA2CNCF1CACNA2D1 | |
| SCHEMBL25571706 | 0.86 | NCF1 (0.54) | ACHECHRM5ADRA2CNCF1CACNA2D1 | |
| SCHEMBL24319343 | 0.85 | CHRM5 (0.50) | ACHECHRM5ADRA2CNCF1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ACHE 2091/4885CHRM5 4531/4885ADRA2C 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.